Solan Headlines

Acquired Hemophilia A Pipeline

(New York, USA) DelveInsight’s Acquired Hemophilia A Pipeline Insight 2023 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Acquired Hemophilia A Pipeline domain.

Request a sample and discover more about the scope of the report offerings @ Acquired Hemophilia A Pipeline

Some of the essential takeaways from the Acquired Hemophilia A Pipeline report:

• DelveInsight’s Acquired Hemophilia A Pipeline analysis depicts a robust space with 10+ active players proactively working to develop 10+ pipeline treatment therapies. 
• Some of the key Acquired Hemophilia A companies working to develop potential drug candidates to improve the Acquired Hemophilia A treatment scenario include Pfizer, Novo Nordisk, Hema Biologics, Hoffman-La-Roche, Takeda, Poseida Therapeutics, Takeda and many others.
• Essential Acquired Hemophilia A Pipeline therapies such as Marstacimab, Mim8, Eptacog Beta (LR769), and others are under development in different phases of clinical studies.
• The U.S. FDA has granted Fast Track Designation (FTD) for Efanesoctocog alfa, developed by Sanofi for Acquired Hemophilia A treatment.
• In October 2021, Poseida Therapeutics and Takeda started working together to develop non-viral gene therapies for Acquired Hemophilia And other genetic diseases. Through a collaboration, Takeda Pharmaceutical will apply Poseida Therapeutics’ technologies to develop up to eight gene therapies including a Acquired Hemophilia A candidate under
• Giroctocogene fitelparvovec is being developed as part of a collaboration agreement for the global development and commercialization of gene therapies for Acquired Hemophilia A between Sangamo and Pfizer. In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug (IND) application to Pfizer. The US FDA granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy (RMAT) designations to giroctocogene fitelparvovec, which also received Orphan Medicinal Product Designation from the European Medicines Agency.

Request a sample and discover more about the Acquired Hemophilia A drugs and treatment scenario @ https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight

The Acquired Hemophilia A Pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Acquired Hemophilia A products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Acquired Hemophilia A Pipeline landscape.

Acquired Hemophilia A Overview

Hemophilia is an inherited rare bleeding disorder where blood doesn’t clot in a regular way because the person affected doesn’t make enough blood-clotting proteins (clotting factors). Without these factors, patients cannot stop bleeding when they are injured. Hemophilia symptoms depend on the level of clotting factors. If the clotting-factor level is mildly reduced, it might bleed only after surgery or trauma. If the deficiency is severe, one can bleed easily for seemingly no reason. Small cuts are not much dangerous but internal bleeding is very harmful to Hemophiliac patients. The main concern of this genetic disorder is internal bleeding in elbows, knees, ankles, and other joints. Internal bleeding can damage the organs and tissues and can also be potentially life-threatening.

There are several types of Hemophilia such as Acquired Hemophilia A, Hemophilia B, Hemophilia C, and Von Willebrand disease Hemophilia classification is done on the basis of clotting factors like Acquired Hemophilia A is caused by factor VIII, Hemophilia  B is caused by factor IX.  Hemophilia diagnosis includes screening tests such as Complete Blood Count (CBC), Activated Partial Thromboplastin Time (APTT) Test, Prothrombin Time (PT) Test, Fibrinogen Test, and clotting factor tests. 

Find out more about the disease and recently developing strategies @ Acquired Hemophilia A Pipeline Assessment – https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight

Acquired Hemophilia A Pipeline Drugs

• Eptacog Beta (LR769): Hema Biologics
• Mim8: Novo Nordisk
• Marstacimab:Pfizer
• And many others

Learn more about the novel and emerging Acquired Hemophilia A Pipeline therapies @ https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight

Acquired Hemophilia A Therapeutics Assessment

The Acquired Hemophilia A Pipeline report proffers an integral view of the Acquired Hemophilia A emerging novel therapies segmented by Stage, Product Type, Mechanism of Action, Route of Administration, and Molecule Type.

Scope of the Acquired Hemophilia A Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Acquired Hemophilia A Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Acquired Hemophilia A Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
• Therapeutics Assessment By Acquired Hemophilia A Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous
• Therapeutics Assessment By Acquired Hemophilia A Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules
• coagulation factor replacements, Factor X stimulants, Factor VIII replacements, Gene transference, Cell replacements, Factor X stimulants, Factor VIIa stimulants

• Key Acquired Hemophilia A Companies: Pfizer, Novo Nordisk, Hema Biologics, Hoffman-La-Roche, Takeda, Poseida Therapeutics, Takeda and many others.

• Key Acquired Hemophilia A Pipeline Therapies: Marstacimab, Mim8, Eptacog Beta (LR769), and others.

Request for a free sample copy here @ https://www.delveinsight.com/sample-request/acquired-hemophilia-a-pipeline-insight

Table of content:

Introduction

Executive Summary

Acquired Hemophilia A: Overview

• Acquired Hemophilia A Causes
• Acquired Hemophilia A Mechanism of Action
• Acquired Hemophilia A Signs and Symptoms
• Acquired Hemophilia A Diagnosis
• Acquired Hemophilia A Disease Management

Acquired Hemophilia A Pipeline Therapeutics

Acquired Hemophilia A Therapeutic Assessment

Acquired Hemophilia A – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Acquired Hemophilia A Collaboration Deals

Late Stage Products (Phase III)

Marstacimab:Pfizer

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

Mim8: Novo Nordisk

Pre-clinical and Discovery Stage Products

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Acquired Hemophilia A Companies

Acquired Hemophilia A Key Products

Acquired Hemophilia A Unmet Needs

Acquired Hemophilia A Market Drivers and Barriers

Acquired Hemophilia A- Future Perspectives and Conclusion

Acquired Hemophilia A Analyst Views

Acquired Hemophilia A Key Companies

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting